PASADENA, CA, USA I October 31, 2019 I Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at the 2019 North American Cystic Fibrosis Conference (NACFC) on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis (CF), which is a rare disease caused by genetic mutations that lead to mucus buildup in the lungs and pancreas. Arrowhead is currently conducting IND/CTA-enabling studies to support regulatory filings in the first half of 2020 for first-in-human studies.
Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead, said: “We view the epithelial sodium channel, ENaC, as an exciting target in the treatment of CF and one that is well suited to an RNAi-based intervention. Based on its mechanism of action, ARO-ENaC has the potential to provide clinical benefit to all patients with CF, regardless of genotype, and may prove useful in combination with existing or new CFTR-targeted therapies. The data presented today show that ARO-ENaC can accelerate mucociliary clearance in normal sheep and also preserve airway physiology in a sheep disease model of impaired mucociliary clearance. In addition, animal models indicate that ARO-ENaC can reduce ENaC activity in the lung but avoid impact in the kidney, which has historically been a key safety liability for prior investigational small molecule ENaC inhibitors.”
ARO-ENaC is designed to reduce production of the epithelial sodium channel alpha subunit (αENaC) in the airways of the lung. In patients with CF, increased ENaC activity contributes to airway dehydration and reduced mucociliary transport. In CF lung disease, patients can have difficulty breathing and experience frequent and persistent lung infections. Various human genetic studies have validated ENaC as a potential therapeutic target for CF, but the development of inhaled small molecule ENaC inhibitors has been limited by on-target renal toxicity and short duration of action in the lung.
Key points presented at NACFC 2019 include the following:
- Arrowhead’s pulmonary epithelial TRiM™-enabled delivery platform increased potency of RNAi trigger-mediated silencing of αENaC mRNA, and durably reduced whole lung gene expression in rodents
- In normal sheep, inhaled ARO-ENaC produced dose-dependent acceleration of mucociliary clearance, which is a lung physiology endpoint linked to pulmonary function in patients with CF
- Inhaled ARO-ENaC preserves lung clearance in a sheep disease model of mucostasis
- ARO-ENaC may offer a new renal-sparing, genotype-agnostic therapy for all patients with CF, and exhibiting the potential for an extended duration of action that should minimize treatment burden
- Arrowhead is also expanding its pulmonary delivery platform to address additional lung disease targets, particularly those that are inaccessible to traditional small molecule or antibody approaches
A copy of the poster presentation can be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
SOURCE: Arrowhead Pharmaceuticals
Post Views: 326
PASADENA, CA, USA I October 31, 2019 I Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at the 2019 North American Cystic Fibrosis Conference (NACFC) on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis (CF), which is a rare disease caused by genetic mutations that lead to mucus buildup in the lungs and pancreas. Arrowhead is currently conducting IND/CTA-enabling studies to support regulatory filings in the first half of 2020 for first-in-human studies.
Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead, said: “We view the epithelial sodium channel, ENaC, as an exciting target in the treatment of CF and one that is well suited to an RNAi-based intervention. Based on its mechanism of action, ARO-ENaC has the potential to provide clinical benefit to all patients with CF, regardless of genotype, and may prove useful in combination with existing or new CFTR-targeted therapies. The data presented today show that ARO-ENaC can accelerate mucociliary clearance in normal sheep and also preserve airway physiology in a sheep disease model of impaired mucociliary clearance. In addition, animal models indicate that ARO-ENaC can reduce ENaC activity in the lung but avoid impact in the kidney, which has historically been a key safety liability for prior investigational small molecule ENaC inhibitors.”
ARO-ENaC is designed to reduce production of the epithelial sodium channel alpha subunit (αENaC) in the airways of the lung. In patients with CF, increased ENaC activity contributes to airway dehydration and reduced mucociliary transport. In CF lung disease, patients can have difficulty breathing and experience frequent and persistent lung infections. Various human genetic studies have validated ENaC as a potential therapeutic target for CF, but the development of inhaled small molecule ENaC inhibitors has been limited by on-target renal toxicity and short duration of action in the lung.
Key points presented at NACFC 2019 include the following:
- Arrowhead’s pulmonary epithelial TRiM™-enabled delivery platform increased potency of RNAi trigger-mediated silencing of αENaC mRNA, and durably reduced whole lung gene expression in rodents
- In normal sheep, inhaled ARO-ENaC produced dose-dependent acceleration of mucociliary clearance, which is a lung physiology endpoint linked to pulmonary function in patients with CF
- Inhaled ARO-ENaC preserves lung clearance in a sheep disease model of mucostasis
- ARO-ENaC may offer a new renal-sparing, genotype-agnostic therapy for all patients with CF, and exhibiting the potential for an extended duration of action that should minimize treatment burden
- Arrowhead is also expanding its pulmonary delivery platform to address additional lung disease targets, particularly those that are inaccessible to traditional small molecule or antibody approaches
A copy of the poster presentation can be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
SOURCE: Arrowhead Pharmaceuticals
Post Views: 326
